CytoMed (NASDAQ: GDTC) details trials and seeks input on therapy access

Rhea-AI Filing Summary

CytoMed Therapeutics Limited, a Singapore-based clinical stage cell therapy company, provided a new year update on its pipeline, funding and shareholder engagement. The company is advancing donor-derived gamma delta T cell and Natural Killer cell immunotherapies, including support from Enterprise Singapore for its Natural Killer cell work through subsidiary LongevityBank. Management believes it has enough resources to fund activities for at least a year and is exploring licensing, real estate asset monetisation and strategic partnerships to support the business with less dilution.

CytoMed highlighted a Memorandum of Understanding with Universiti Malaya to run a first-in-human Phase I trial of its allogeneic unmodified gamma delta T cells in no-option cancer patients in Malaysia, targeting an Investigational New Drug submission before June. This complements an ongoing Phase I CAR-T trial in Singapore, where six patients have been treated. The company also cited a recent co-authored preclinical publication with MD Anderson Cancer Center on acute myeloid leukemia and noted that its chairman intends to increase his shareholding. CytoMed is seeking shareholder feedback on a proposed scheme allowing shareholders, subject to medical approval and local rules, to use their shareholdings to access its donor-derived allogeneic unmodified gamma delta T cell therapy.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Exact name of registrant as specified in its charter)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On January 13, 2026, CytoMed Therapeutics Limited (the “Company”) issued a press release announcing its new year update and inviting shareholders to provide feedback on a proposal to enhance shareholders’ patient capital.

A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Press Release dated January 13, 2026, titled: “CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital”

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
	By:	/s/ CHOO Chee Kong
	Name:	CHOO Chee Kong
Date: January 13, 2026	Title:	Director and Chairman

Exhibit 99.1

CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital

Singapore, (January 13, 2026) – CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, is pleased to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements, CytoMed through new subsidiary LongevityBank is also diversifying its product pipeline through the process development of clinical-grade cord blood-derived Natural Killer cells. In so doing, it will enhance access to rare and valuable cord blood as sources for cell-based allogeneic therapies. In addition to CytoMed’s gamma delta T cells, Natural Killer cells also express receptors that recognise stress ligands, allowing them to be cytotoxic tools to combat a wide variety of solid and hematological cancers.  Notably, CytoMed’s efforts in development of Natural Killer cell therapy has recently received support from Enterprise Singapore, a Singapore government agency championing enterprise development.

For this new year 2026, the Company believes it has enough resources to continue funding its activities for at least a year given our low-cost infrastructure in Southeast Asia. Besides the usual capital market routes, CytoMed can look to licencing and asset monetisation from real estate properties which it owns and uses for operation. We are also continuously exploring proposals with sustainable benefits as we explore with long-term strategic partners including synergistic biotechs and hospitals which can strengthen the business and international aspects with less dilution. Notably CytoMed was ranked 4 out of 5 points in terms of investment potential in 2025 December’s Morning Star publication. As a matter of full disclosure, our Chairman Peter Choo intends to increase his shareholding in the Company and will make the relevant announcement as soon as possible.

As announced on December 8, 2025, CytoMed has entered into a Memorandum of Understanding with Universiti Malaya (“UM”) to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed’s patented allogeneic unmodified Gamma Delta (γδ) T cells (CTM-GDT) (without genetically modifying the cells to express any receptor) for no-option cancer patients in Malaysia. We target to submit an Investigational New Drug application to the Malaysian authorities before June this year. This initiative complements CytoMed’s ongoing first-in-human Phase I chimeric antigen receptor T (CAR T) cell clinical trial at National University Hospital Singapore, which uses γδ T cells modified to express a CAR (CTM-N2D) targeting various cancer types, including advanced colorectal cancer, lymphoma, multiple myeloma, lung cancer, ovarian cancer, hepatocellular carcinoma. To date, six patients had been treated at two dosage levels in Singapore.

Unmodified gamma delta T cells have been demonstrated in international clinical trials to have potential to kill cancer cells including brain cancers. CytoMed is co-author in a recent September/ October 2025 publication of a preclinical study, in a research article entitled “Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “off-the-shelf” Immunotherapy Approach”. The study results from this collaborative research with The University of Texas, MD Anderson Cancer Center (MDACC), are suggesting the great potential of CytoMed’s allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). This collaboration with MDACC is under a previously announced research agreement in May 2023. The research article is now publicly and freely online at Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach.

Chairman Peter Choo commented “ Our allogeneic CAR T cells are on clinical trial and many no-option cancer patients with unmet needs or failed conventional cancer treatments have approached us. Healthcare cost in the West is prohibitive and is the main reason why international medical tourism is booming in Southeast Asia where costs are substantially lower than in the West. We believe we can manufacture clinical grade therapeutics in Southeast Asia at low cost”.

In line with above, the Company intends to seek feedback and opinion from shareholders on a novel scheme under which a shareholder can use his shareholding to get access to the Company’s donor-derived allogeneic unmodified gamma delta T cells subject to the doctor’s approval and home country regulations. Shareholders are encouraged to contact the Company for further information and share their ideas.

About CytoMed Therapeutics Limited (CytoMed)

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company’s current and future pre-clinical studies and clinical trials and the Company’s R&D programs; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Contact :

CytoMed Therapeutics Limited

enquiry@cytomed.sg

Attention : Evelyn Tan, Chief Corporate Officer

FAQ

What is CytoMed Therapeutics (GDTC) updating investors about in this 6-K?

CytoMed provides a new year update on its cell therapy pipeline, funding outlook, clinical collaborations and a proposal to seek shareholder feedback on a scheme linking shareholdings to potential access to its donor-derived allogeneic unmodified gamma delta T cell therapy, subject to medical and regulatory conditions.

How long does CytoMed Therapeutics (GDTC) believe its current resources will last?

The company states it believes it has enough resources to continue funding its activities for at least a year, supported by its low-cost infrastructure in Southeast Asia.

What new clinical trial plans did CytoMed Therapeutics (GDTC) describe?

CytoMed has a Memorandum of Understanding with Universiti Malaya to run a multi-site, first-in-human Phase I clinical trial in Malaysia using its patented allogeneic unmodified gamma delta T cells for no-option cancer patients, and it targets submitting an Investigational New Drug application before June.

What progress has CytoMed Therapeutics (GDTC) made in its ongoing CAR-T trial?

The company reports an ongoing first-in-human Phase I CAR T cell clinical trial at National University Hospital Singapore using modified gamma delta T cells, with six patients treated at two dosage levels to date across various advanced cancers.

What collaboration and publication did CytoMed Therapeutics (GDTC) highlight?

CytoMed is co-author of a September/October 2025 preclinical study with The University of Texas MD Anderson Cancer Center on donor-derived Vγ9Vδ2 T cells for acute myeloid leukemia, which suggests potential for its allogeneic gamma delta T cell therapy and is based on a research agreement announced in May 2023.

How does CytoMed Therapeutics (GDTC) plan to support its capital needs beyond traditional markets?

In addition to usual capital market routes, CytoMed mentions potential licensing, asset monetisation from real estate properties it owns and uses for operations, and exploring proposals with long-term strategic partners such as synergistic biotechs and hospitals to strengthen the business with less dilution.

What shareholder-related initiatives did CytoMed Therapeutics (GDTC) announce?

The company notes that its chairman intends to increase his shareholding and that it plans to seek shareholder feedback on a scheme where shareholders could use their shareholding to access its donor-derived allogeneic unmodified gamma delta T cell therapy, subject to doctor approval and home country regulations.